HER2 evaluation by IHC or ISH before trastuzumab administration is essential for clinical practice, and many practical guidelines recommend that patients with unresectable locally advanced, recurrent, or metastatic adenocarcinoma of the stomach or GEJ be tested for HER2 status in tumor tissues. This evidence concerns the gene ERBB2 and neoplasm.